Efficacy of adalimumab in a patient with hidradenitis suppurativa and concomitant ulcerative colitis

Introduction: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) are both chronic inflammatory diseases with a big impact in the quality of life of the patients. It has been described a higher prevalence of HS among patients diagnosed with IBD, especially Crohn disease. Some drugs used in HS, such as antibiotics, can be harmful for IBD patients and they may trigger flare ups. Adalimumab is anti-TNF drug which is approved for the treatment of both diseases, being the doses similar in both disorders.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research